<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002438</url>
  </required_header>
  <id_info>
    <org_study_id>235B</org_study_id>
    <secondary_id>MSG 28</secondary_id>
    <secondary_id>ITR-USA-73</secondary_id>
    <nct_id>NCT00002438</nct_id>
  </id_info>
  <brief_title>A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients</brief_title>
  <official_title>Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of itraconazole versus placebo for prevention of&#xD;
      histoplasmosis in HIV-infected patients with CD4 counts &lt; 150 cells/mm3 who reside where&#xD;
      histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing&#xD;
      other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant&#xD;
      oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Histoplasmosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Residence in an area endemic for H. capsulatum.&#xD;
&#xD;
          -  Absolute CD4 count &lt; 150 cells/mm3.&#xD;
&#xD;
          -  No current or past active histoplasmosis.&#xD;
&#xD;
          -  No other active fungal infection.&#xD;
&#xD;
          -  Life expectancy of at least 1 year.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Life-threatening infection or malignancy other than cutaneous Kaposi's sarcoma.&#xD;
&#xD;
          -  Inability to take oral medication.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Systemically-active antifungals.&#xD;
&#xD;
          -  Investigational drugs (expanded access drugs are acceptable).&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Terfenadine.&#xD;
&#xD;
          -  Astemizole.&#xD;
&#xD;
          -  Phenobarbital.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Carbamazepine.&#xD;
&#xD;
          -  H2 blockers.&#xD;
&#xD;
          -  Omeprazole.&#xD;
&#xD;
          -  Continual antacids.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        History of intolerance to imidazole or azole compounds.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 1 month prior to study entry:&#xD;
&#xD;
          -  Investigational drugs (expanded access drugs are acceptable).&#xD;
&#xD;
        Excluded within 15 days prior to study entry:&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Terfenadine.&#xD;
&#xD;
          -  Astemizole.&#xD;
&#xD;
          -  Phenobarbital.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Carbamazepine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Infectious Diseases Research Clinic / Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases of Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Missouri at Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Association / Research Med Ctr</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASCC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Michael Threikeld</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Mark A Pierce</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Itraconazole</keyword>
  <keyword>Histoplasmosis</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Histoplasmosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

